Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients.

Millán O, Rafael-Valdivia L, Torrademé E, López A, Fortuna V, Sánchez-Cabus S, López-Púa Y, Rimola A, Brunet M.

Cytokine. 2013 Feb;61(2):556-64. doi: 10.1016/j.cyto.2012.10.026. Epub 2012 Dec 21.

PMID:
23265966
2.

Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients.

Uemoto S, Ozawa K, Kaido T, Mori A, Fujimoto Y.

Clin Exp Immunol. 2016 Apr;184(1):126-36. doi: 10.1111/cei.12740. Epub 2016 Jan 11.

3.

Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study.

Millán O, Rafael-Valdivia L, San Segundo D, Boix F, Castro-Panete MJ, López-Hoyos M, Muro M, Valero-Hervás D, Rimola A, Navasa M, Muñoz P, Miras M, Andrés A, Guirado L, Pascual J, Brunet M.

Clin Immunol. 2014 Oct;154(2):141-54. doi: 10.1016/j.clim.2014.07.007. Epub 2014 Aug 1.

PMID:
25088788
4.

Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy.

Millán O, Benitez C, Guillén D, López A, Rimola A, Sánchez-Fueyo A, Brunet M.

Clin Immunol. 2010 Dec;137(3):337-46. doi: 10.1016/j.clim.2010.08.004. Epub 2010 Sep 6.

PMID:
20822959
5.

Effect of immunosuppressive regimen on acute rejection and liver graft function.

Ziolkowski J, Paczek L, Niewczas M, Senatorski G, Oldakowska-Jedynak U, Wyzgal J, Foroncewicz B, Mucha K, Zegarska J, Nyckowski P, Zieniewicz K, Patkowski W, Krawczyk M, Ziarkiewicz-Wroblewska B, Gornicka B.

Transplant Proc. 2003 Sep;35(6):2281-3.

PMID:
14529915
6.

A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil.

Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, Oellerich M, Ramadori G.

Transplantation. 2001 Feb 27;71(4):508-15.

PMID:
11258429
7.

Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.

Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.

Clin Ther. 2005 Apr;27(4):463-9.

PMID:
15922819
8.

Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells.

Ahmed M, Venkataraman R, Logar AJ, Rao AS, Bartley GP, Robert K, Dodson FS, Shapiro R, Fung JJ, Zeevi A.

Ther Drug Monit. 2001 Aug;23(4):354-62.

PMID:
11477316
9.

A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.

Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, Starzl TE, Fung JJ.

Transplantation. 2001 Sep 27;72(6):1091-7.

10.

Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.

Jain A, Kashyap R, Kramer D, Dodson F, Hamad I, Starzl TE, Fung JJ.

Transplant Proc. 2001 Feb-Mar;33(1-2):1342-4. No abstract available.

11.

Early coupled up-regulation of interleukin-12 receptor beta-1 in CD8+ central memory and effector T cells for better clinical outcomes in liver transplant recipients.

Uemoto S, Ozawa K, Kaido T, Mori A, Fujimoto Y, Ogawa K.

Clin Exp Immunol. 2015 Aug;181(2):373-84. doi: 10.1111/cei.12588.

12.

Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group.

Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E.

Transplantation. 1999 Dec 27;68(12):1865-74.

PMID:
10628766
13.

Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.

Theruvath TP, Saidman SL, Mauiyyedi S, Delmonico FL, Williams WW, Tolkoff-Rubin N, Collins AB, Colvin RB, Cosimi AB, Pascual M.

Transplantation. 2001 Jul 15;72(1):77-83.

PMID:
11468538
14.

Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation.

Briem-Richter A, Leuschner A, Krieger T, Grabhorn E, Fischer L, Nashan B, Haag F, Ganschow R.

Pediatr Transplant. 2013 Dec;17(8):757-64. doi: 10.1111/petr.12161. Epub 2013 Oct 6.

PMID:
24164827
15.

Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.

Figueras J, Bernardos A, Prieto M, Gómez M, Rimola A, Ortiz de Urbina J, Cuervas-Mons V, de la Mata M, Dominguez-Granados R.

Transplant Proc. 2002 Aug;34(5):1511-3. No abstract available.

PMID:
12176461
16.

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.

Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.

Transplantation. 2005 Aug 27;80(4):457-65.

PMID:
16123718
17.

A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.

Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, Maggi U, Melada E, Paone G, Rossi G.

Transplant Proc. 2005 May;37(4):1697-9.

PMID:
15919435
18.

Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection.

Boleslawski E, Conti F, Sanquer S, Podevin P, Chouzenoux S, Batteux F, Houssin D, Weill B, Calmus Y.

Transplantation. 2004 Jun 27;77(12):1815-20.

PMID:
15223897
19.

Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus.

Daly I, Jain A, Reyes J, Fung J.

Transplant Proc. 2002 Aug;34(5):1503. No abstract available.

PMID:
12176458
20.

Supplemental Content

Support Center